Enveric Biosciences Inc — Quarterly Cash Flow (NASDAQ:ENVB) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics

Quarterly Annual

Total assets 4.79 M3.08 M5.1 M3.55 M4.36 M Total liabilities 839.17 K1.49 M1.18 M1.36 M905.88 K Total equity 3.95 M1.59 M3.92 M2.18 M3.46 M Total liabilities & shareholders' equities 4.79 M3.08 M5.1 M3.55 M4.36 M Total debt ————— Net debt —————

Notizie

Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested - Enveric Biosciences (NASDAQ:ENVB)

Le azioni di Enveric Biosciences salgono dopo nuovi dati sul farmaco principale

Enveric Biosciences stock soars after revealing new data on lead drug candidate

Il farmaco principale di Enveric attiva vie chiave legate al sollievo dalla depressione

Enveric’s lead drug candidate activates key pathways linked to depression relief

Enveric Advances Lead Drug With New Findings On Key Brain Receptor Signals - Enveric Biosciences (NASDAQ:ENVB)

Enveric Biosciences registra 1,35 milioni di dollari in nuove azioni nell’ambito dell’accordo ATM

Enveric Biosciences registers $1.35 million in new shares under ATM agreement

Enveric licenses RCANN trademark portfolio to TOTEC Pharma

Enveric Biosciences chiude un’offerta diretta registrata da 1,5 milioni di dollari

Enveric Biosciences closes $1.5 million registered direct offering

Enveric Biosciences raises $1.5 million in registered direct offering